Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC).

Overview

authors

Shariat, Shahrokh
Pradere, B

publication date

January 13, 2026

published in

Annals of oncology : official journal of the European Society for Medical Oncology Journal

Identity

Scopus Document Identifier

105030374849

Digital Object Identifier (DOI)

10.1016/j.annonc.2026.01.003

PubMed ID

41539604

Additional Document Info

has global citation frequency

1

volume

37

issue

5